Clinical course of high-risk patients diagnosed with antiphospholipid syndrome.
about
Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndromeThrombotic risk assessment in antiphospholipid syndrome: the role of new antibody specificities and thrombin generation assayAssessing the risk of recurrent venous thromboembolism--a practical approachRecurrent venous thromboembolism: what is the risk and how to prevent itRecommended Therapeutic INR Range for Patients with Antiphospholipid Syndrome on Warfarin Anticoagulation: Is Moderate-Intensity (INR 2.0 - 3.0) or High-Intensity (INR 3.1 - 4.0) Better for Reducing Risk of Recurrent Thromboembolic Events?The clinical significance of antiphospholipid antibodies in systemic lupus erythematosusAssociations of antiphospholipid antibodies with splanchnic vein thrombosis: a systematic review with meta-analysisDirect oral anticoagulants in hypercoagulable states.Acquired immune-mediated thrombophilia in lymphoproliferative disorders.Clinical manifestations and anti-phospholipid antibodies in 712 patients with systemic lupus erythematosus: evaluation of two diagnostic assays.Difficult clinical situations in the antiphospholipid syndrome.Review on Effectiveness of Primary Prophylaxis in aPLs with and without Risk Factors for Thrombosis: Efficacy and SafetyLeg ulcers in antiphospholipid syndrome secondary to systemic lupus erythematosus treated with intravenous immunoglobulin.Diagnosis of antiphospholipid syndrome in routine clinical practiceNew therapeutic targets for the antiphospholipid syndrome.Antiphospholipid Syndrome Clinical Research Task Force report.Interpretation of laboratory data and need for reference laboratories.The relationship between mean platelet volume and thrombosis recurrence in patients diagnosed with antiphospholipid syndromeGuidelines for the treatment of antiphospholipid syndrome."New" antigenic targets and methodological approaches for refining laboratory diagnosis of antiphospholipid syndromeTreatment of the antiphospholipid syndrome.Systemic lupus erythematosus and thrombosis.Treatment of Thrombotic Antiphospholipid Syndrome: The Rationale of Current Management-An Insight into Future Approaches.Histological antiphospholipid-associated nephropathy versus lupus nephritis in patients with systemic lupus erythematosus: an observational cross-sectional study with longitudinal follow-upHigh prevalence of prothrombotic abnormalities in multifocal osteonecrosis: description of a series and review of the literature.Identification of a Monoclonal Antibody That Attenuates Antiphospholipid Syndrome-Related Pregnancy Complications and Thrombosis.Evaluation of the diagnostic potential of antibodies to beta2-glycoprotein 1 domain 1 in Chinese patients with antiphospholipid syndromeThe antiphospholipid syndrome: still an enigmaDetection of multiple annexin autoantibodies in a patient with recurrent miscarriages, fulminant stroke and seronegative antiphospholipid syndrome.Association between antiphospholipid antibodies and all-cause mortality among end-stage renal disease patients with and without SLE: a retrospective cohort studyRivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial.Epidemiology of recurrent venous thrombosisRecent advances in understanding antiphospholipid syndrome.Inhibition of thrombotic properties of persistent autoimmune anti-β2GPI antibodies in the mouse model of antiphospholipid syndromeClinical audit of antiphospholipid antibody testing in tertiary practice: towards improved relevance in thrombophilia investigations.Laboratory testing for the antiphospholipid syndrome: making sense of antiphospholipid antibody assays.'Criteria' aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, Texas, April 2010.Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment.Guidelines on the investigation and management of antiphospholipid syndrome.Secondary prevention in thrombotic antiphospholipid syndrome.
P2860
Q24185949-FF09D605-399E-4A6E-BF6E-F2C6301EFEAFQ26739950-65F4E6C3-410C-4305-894E-F29168190096Q26796430-63F699F5-6002-419F-8A20-FD3D5F137EF1Q26826847-CF178E1E-D176-42AA-B6BB-B05449CBDA8EQ28071739-5ED51F6D-FF83-4E15-89B6-239A30C71E1BQ28072610-A40D8DC6-8BC7-485B-A3D3-F071F9B0A073Q28082873-8A21952D-7107-4250-A0C8-CEFAE7F98526Q30275936-AFFCA518-9B08-415B-B566-025895D3A65BQ33396280-1A8FB811-52A8-4969-B6BA-5EC034C9AEA6Q33404418-B82EB265-577D-472E-BAC6-6D54F054D484Q33421814-48423899-22D1-4097-8CE8-A5A66752F51FQ33692770-CB9A98A9-1B2C-4954-82F7-0B03D75C3C6BQ33890858-C189BC7C-965A-43DC-8D4A-7B58117364CBQ33939826-D2846CE9-1BA1-4D1C-A400-1CD8D5D39B01Q34140319-696F1CA4-AEA8-433D-8E86-77FC12F1928EQ34163321-B585F835-171D-422B-9396-24BA92DE23F0Q34283606-BB924A17-C596-48F6-8642-B37491B29AE7Q34402456-E1A089EF-9F1A-4271-8687-9D4F1635411CQ34821893-4B6469C4-8383-4B13-974D-99D2ABDF9427Q35250419-0EB76D30-7BED-4E59-A927-B4656E7714C3Q35308972-D5803B1F-1212-4FE9-B93B-511F99C5AACCQ35530248-C7FCFC04-D647-450C-814D-369F4424C00DQ35621012-A26C4D77-ECBA-4811-B339-E08E867D3AA7Q35645573-69C569DA-076A-49FD-9E8B-FD1926A2EE37Q36009039-0243A3C1-77BF-4DC6-B9EE-609314E0DFE2Q36087118-2ECE30F3-53C9-48A3-983D-0CBF91D5C047Q36774243-9958F9BB-E7EB-4DD1-9C2C-8CE79E10C01AQ36928593-99A4A9A1-D704-48E7-9BDA-35801FF58074Q37011051-FBA48E28-79B5-4F09-9BBC-A173D0C685A8Q37228076-C614B458-B73A-4AE1-B1C5-3B6F01552542Q37230504-7D18BEC8-747D-4667-9D0B-77A3C418732FQ37370722-C2222E80-1233-40AC-AC51-552210CBCE3CQ37577693-69E6699E-995F-4C97-98C9-C0D2BC3F4766Q37585221-CEF212BB-8BBB-4334-88BD-F6C52ADB82E1Q37777423-D6D91796-5016-4C13-AE89-2138B2EBEDD4Q37833102-74F788AE-2E06-4321-822B-FB13CABF5434Q37838098-1CE09CA5-3190-4A5D-9B9D-7C390C3D91BAQ37842673-B1B8B5B9-14A3-4017-97D2-9AD3AB1541A2Q37982121-60292D3A-99CB-4CC7-A095-8AC8450D48E4Q38013589-F76C1E56-0AA5-4F74-96AC-0471D482EAA9
P2860
Clinical course of high-risk patients diagnosed with antiphospholipid syndrome.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Clinical course of high-risk patients diagnosed with antiphospholipid syndrome.
@en
Clinical course of high-risk patients diagnosed with antiphospholipid syndrome.
@nl
type
label
Clinical course of high-risk patients diagnosed with antiphospholipid syndrome.
@en
Clinical course of high-risk patients diagnosed with antiphospholipid syndrome.
@nl
prefLabel
Clinical course of high-risk patients diagnosed with antiphospholipid syndrome.
@en
Clinical course of high-risk patients diagnosed with antiphospholipid syndrome.
@nl
P2093
P1476
Clinical course of high-risk patients diagnosed with antiphospholipid syndrome.
@en
P2093
A Ruffatti
D Barcellona
F Marongiu
P304
P356
10.1111/J.1538-7836.2009.03674.X
P577
2009-10-30T00:00:00Z